Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Don’t Miss, Industry

11 Jan 2022

News You Might Have Missed: Jan 11th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed....

By Jason Najum

Industry

10 Jan 2022

Big Pharma Gets Into Psychedelics With $5M Mindset Deal

This $5 million investment, made through its McQuade Center for Strategic Research and Development will support the discovery and development of Mindset’s novel assets (with related rights to potential licensing...

By Jason Najum

Law & Politics

5 Jan 2022

Canada Amends Special Access to Psychedelics

Today we received the official notice for the government to the SAP....

By Jason Najum

Industry

4 Jan 2022

MindMed Successfully Completes Phase 1 Trial of 18-MC

18-MC is MindMed's non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

22 Dec 2021

MindMed Provides Update on Phase 2b LSD Trial

It’s been a rough 6 months for most of the psychedelic medicine industry....

By Jason Najum

Don’t Miss

20 Dec 2021

News You Might Have Missed: December 20, 2021

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed....

By Jason Najum

Law & Politics

16 Dec 2021

Canada Grants 3 Patients Exemption to Use Psilocybin for Mental Health

In what may turn out to be a major milestone for drug and mental health reform, the Canadian government has granted 3 patients an exemption for the use of psilocybin...

By Jason Najum

Industry

15 Dec 2021

Cybin Nears Patent Approval for CYB004

Cybin's patent covers deuterated forms of DMT and 5-MeO-DMT, and CYB004 is looking at anxiety disorders — molecules with very interesting potential and markets with huge unmet needs....

By Jason Najum

Don’t Miss

13 Dec 2021

News You Might Have Missed: December 13, 2021

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.